Tuberculosis Diagnostic Market: Rapid Molecular Testing and Drug-Resistance Detection Create New Growth Opportunities

The global Tuberculosis Diagnostic Market is expanding as healthcare systems, governments, and diagnostic companies increase efforts to identify tuberculosis earlier and improve detection of drug-resistant infections. According to Maximize Market Research, the global Tuberculosis Diagnostic Market was valued at USD 3.49 billion in 2022 and is projected to reach approximately USD 4.86 billion by 2029, growing at a CAGR of 4.82% during 2023–2029. Rising tuberculosis prevalence, the burden of multidrug-resistant TB, increasing government programs, and investment in advanced diagnostic technologies are supporting market development.

* Request a Free Sneak Peek: https://www.maximizemarketresearch.com/request-sample/94559/ 

Market Estimation, Growth Drivers and Opportunities

The increasing global burden of tuberculosis remains a fundamental driver for diagnostic demand. Rapid identification of TB and antimicrobial resistance is essential for appropriate treatment and limiting transmission, particularly in high-burden regions. Government screening programs, public-health initiatives, and increased expenditure on diagnostic research are supporting market expansion. The development of faster molecular tests, point-of-care platforms, automated laboratory systems, digital radiography, and technologies capable of identifying drug resistance is creating additional opportunities. WHO's 2025 consolidated TB diagnostic guidance introduced new diagnostic technology classes and expanded recommendations for testing, reflecting continued development of the diagnostic landscape. WHO also reported that almost 100 TB diagnostic products were in development as of August 2025, including point-of-care tests, automated nucleic-acid amplification tests, targeted next-generation sequencing and computer-aided detection technologies.

U.S. Market Trends and Investment

The U.S. tuberculosis diagnostics market continues to be supported by targeted testing, laboratory modernization and federal funding for TB prevention and control. In January 2025, the CDC announced its five-year TB Elimination and Laboratory Cooperative Agreement, supporting state, local and territorial health departments in TB prevention, laboratory services, surveillance, targeted testing and treatment activities. CDC guidance published in 2025 also emphasizes testing people at increased risk and evaluating individuals with symptoms or positive TB infection tests for TB disease. These programs sustain demand for laboratory diagnostics and rapid testing technologies. In the private-sector technology landscape, Cepheid continued expanding molecular TB diagnostics; in October 2025, the company announced WHO prequalification of its Xpert MTB/XDR test, which runs on GeneXpert systems and provides results in approximately 90 minutes while detecting multiple drug-resistance markers.

Market Segmentation: Largest-Share Segment

Based on test type, the Nucleic Acid Testing segment is projected to hold a significant market share and is expected to record a 5.4% CAGR during the forecast period. MMR attributes its growth to the higher accuracy and faster results offered by nucleic-acid-based testing compared with conventional culture-based approaches. The report covers Radiographic Tests, Nucleic Acid Testing, Cytokine Detection Tests and Other technologies. By end user, the market is segmented into Hospital/Clinics, Diagnostics/Research Laboratories and Other users.

Global Tuberculosis Diagnostic Market, Key Players are
1. Thermo Fisher Scientific, Inc.
2. Alere, Inc.
3. Becton
4. Dickinson and Company
5. F. Hoffmann-La Roche AG
6. LIONEX Diagnostics & Therapeutics GmbH
7. Danaher Corporation
8. Creative Diagnostics
9. QIAGEN
10. Oxford Immunotec Ltd.
11. Hologic, Inc.
12. Cepheid
13. Akonni Biosystems, Inc.
14. bioMerieux SA
15. Epistem Ltd.

Competitive Analysis

MMR identifies Thermo Fisher Scientific, Inc., Alere, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, LIONEX Diagnostics & Therapeutics GmbH, Danaher Corporation, Creative Diagnostics, QIAGEN, Oxford Immunotec Ltd., Hologic, Inc., Cepheid, Akonni Biosystems, Inc., bioMérieux SA, and Epistem Ltd. as key companies. Since the publicly available MMR page does not disclose individual market-share percentages, these companies are discussed as leading/key participants rather than assigned unsupported rankings.

Danaher/Cepheid continues to be a major innovator in molecular TB testing. Cepheid's Xpert MTB/RIF Ultra provides rapid molecular detection, while the Xpert MTB/XDR platform expands resistance detection. The October 2025 WHO prequalification of Xpert MTB/XDR further supports its use as a high-quality molecular diagnostic technology.

bioMérieux strengthened its TB diagnostics portfolio in November 2025 by launching AmPORE-TB, a research-use-only sequencing-based solution developed with Oxford Nanopore Technologies for rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis.

QIAGEN remains active in TB infection testing through molecular and immunological diagnostic technologies, while Thermo Fisher Scientific supports laboratory workflows through molecular biology and microbiology technologies. Becton, Dickinson and Company also remains an established participant in infectious-disease diagnostics and laboratory systems. These developments reflect a broader industry shift toward faster, automated and resistance-focused testing.

Regional Analysis

USA: The U.S. market is supported by CDC-funded TB prevention and laboratory programs, targeted testing strategies and demand for rapid molecular diagnostics.

UK: The UK benefits from established public-health screening systems and continued adoption of molecular diagnostic technologies for infectious diseases. Advanced testing is increasingly important for rapid identification and surveillance of TB.

Germany: Germany's strong healthcare infrastructure, laboratory network and emphasis on antimicrobial-resistance surveillance support demand for advanced TB diagnostics.

France: France's national healthcare system and infectious-disease surveillance infrastructure provide a foundation for adoption of molecular and automated TB testing technologies.

Japan: Japan's mature healthcare infrastructure, diagnostic laboratory capabilities and focus on infectious-disease control support demand for accurate TB testing.

China: China represents an important Asian market because of its large healthcare system and continuing need for TB detection and drug-resistance surveillance. Asia Pacific is expected to experience lucrative growth during the forecast period because of the region's high TB burden, with China and India identified among countries recording high numbers of new cases.

Related Reports: 

NLP in Healthcare and Life Sciences Market https://www.maximizemarketresearch.com/market-report/nlp-in-healthcare-and-life-sciences-market/228435/  

Anti-Wrinkle Products Market https://www.maximizemarketresearch.com/market-report/anti-wrinkle-products-market/228942/ 

Personalized LASIK Surgery Market https://www.maximizemarketresearch.com/market-report/personalized-lasik-surgery-market/230753/ 

Conclusion

The Tuberculosis Diagnostic Market is positioned for steady growth as healthcare systems prioritize earlier detection, rapid molecular testing and identification of drug-resistant tuberculosis. The strongest opportunities are emerging from nucleic-acid testing, point-of-care diagnostics, automated platforms, sequencing technologies and AI-supported radiographic screening. Continued government funding, expanding diagnostic access and innovation in resistance detection will remain important market-growth factors. As WHO and national health programs strengthen diagnostic strategies, companies capable of delivering accurate, rapid, affordable and scalable testing solutions are positioned to address the evolving requirements of TB control worldwide.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com